Adage Capital Partners GP L.L.C. Grows Stock Holdings in Danaher Corporation $DHR

Key Points

• Adage Capital Partners GP L.L.C. has significantly increased its holdings in Danaher Corporation, acquiring an additional 544,151 shares, bringing its total to approximately 981,426 shares valued at $201.19 million.
• During the first quarter, various hedge funds such as Coastal Bridge Advisors LLC and Rakuten Securities Inc. also increased their stakes in Danaher, which now has 79.05% of its stock owned by institutional investors.
• Danaher reported strong quarterly earnings with $1.80 earnings per share, exceeding analyst estimates, and its revenue increased year-over-year by 3.4% to $5.94 billion.

Adage Capital Partners GP L.L.C. boosted its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 124.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 981,426 shares of the conglomerate's stock after acquiring an additional 544,151 shares during the period. Adage Capital Partners GP L.L.C. owned 0.14% of Danaher worth $201,192,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. GHP Investment Advisors Inc. grew its position in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after buying an additional 99 shares during the period. Heck Capital Advisors LLC bought a new position in shares of Danaher in the fourth quarter worth approximately $27,000. Sierra Ocean LLC increased its stake in shares of Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in shares of Danaher during the 1st quarter valued at $31,000. Finally, Dunhill Financial LLC lifted its stake in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after buying an additional 67 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DHR has been the topic of a number of analyst reports. Wells Fargo & Company lowered their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Robert W. Baird lifted their target price on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Guggenheim restated a "buy" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Finally, UBS Group lowered their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $246.35.

Danaher Price Performance

Shares of NYSE:DHR traded up $1.29 during midday trading on Friday, reaching $200.32. 2,837,584 shares of the company were exchanged, compared to its average volume of 2,859,442. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The business's fifty day moving average is $201.93 and its two-hundred day moving average is $199.41. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The stock has a market cap of $143.44 billion, a PE ratio of 42.62, a price-to-earnings-growth ratio of 2.78 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.10% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.